Home Research AG Worm

Worm lab

Novel therapeutic approaches of type I-allergy by immunomodulation

Cooperation partners
Selected Publications
Third party funding projects


The “Allergology” group is focused on immunomodulation of Immunoglobulin E (IgE)-dependent type I allergies. Currently, approx. 20% of the German population are affected by hay fever, allergic asthma or atopic dermatitis. Our research aims to understand  the key molecular and cellular events for the development and maintenance of IgE production. Special interests among our group include the immunomodulatory functions of nuclear receptor ligands that are involved in specific immunotherapy anaphylaxis and regulation of skin homeostasis.

Nuclear receptor ligands include molecules like vitamin D and retinoids. We have shown that vitamin D profoundly modulates B cell activation and hampers the IgE response. We are currently studying  the molecular and cellular signalling events involved in this in more detail and we have also initiated a clinical translation program. In these studies, we target vitamin D receptors in immune cells in vivo and determine the impact on specific allergic symptoms. Our overall aim is to achieve long-term tolerance to allergens.

The studies on specific immunotherapy anaphylaxis and regulation of skin homeostasis include the investigation of patient cohorts upon treatment or bedside reaction.. However, the application of targeted mouse models enables us to set up models with targeted deletion of specific mediators and their receptors to unravel mechanistic functions upon defined pathophysiological conditions.

The overall perspective of our research is to develop novel strategies for innovative treatment protocols in allergyby transfering our experimental data into clinical trials and clinical practice.

Immune modulation

Charité Liaison Group
Continue to Members

Group leader
Prof. Dr. med. Margitta Worm

Dr. rer. nat. Magda Babina, Dr. rer. med. Sabine Dölle-Bierke, Dr. med. Wojciech Francuzik, Dr. Diana Willmes, Dr. Davender Redhu, Kristijan Pazur

PhD student
Padmavathy Ramanarayanan

MD student
Aikaterina Alexiou

Dennis Ernst

Charité Liaison Group
Continue to Cooperation partners
  • Dr. rer. nat. Ria Baumgrass, Deutsches Rheuma-Forschungszentrum Berlin, Cell signaling group, Berlin
  • Dr. med. Thomas Dörner, Med. Klinik mit Schw. Rheumatologie und Klinische Immunologie, Charité – Universitätsmedizin Berlin, Germany
  • Dr. phil. nat. Hermann Eibel, Center for Chronic Immunodeficiency, Universitätsklinikum Freiburg, Germany
  • Dr. rer. nat. Susanne Hartmann, Institut für Immunologie, FB Veterinärmedizin, Freie Universität Berlin, Germany
  • rer. nat. Andreas Hutloff, PhD, Christian-Albrechts-Universität zu Kiel
  • Dr. med. Bastian Opitz, Prof. Dr. med. Martin Witzenrath, Christoph Tabeling, Charité – Universitätsmedizin Berlin, Med. Klinik mit Schw. Infektiologie und Pneumologie, Germany
  • Dr. med. Harald Renz, Philipps-University of Marburg, Dept of Clinical Chemistry and Molecular Diagnostics, Marburg, Germany
  • Dr. rer. nat. Michael Reth, MPI Immunbiology and Epigenetics, Freiburg, Germany
  • Dr. med. Birgit Sawitzki, Charité – Universitätsmedizin Berlin, Institut für Medizinische Immunologie, Germany
  • Dr. rer. nat. Alexander Scheffold, Universitätsklinikum Schleswig-Holstein
  • Dr. med. Hans-Dieter Volk, Charité – Universitätsmedizin Berlin, Klinik für Medizinische Immunologie, Germany
Charité Liaison Group
Continue to Selected Publications
  • Grabenhenrich LB; Dölle S; Ruëff F; Renaudin JM; Scherer K; Pföhler C; Treudler R; Koehli A; Mahler V; Spindler T; Lange L; Bilò MB; Papadopoulos NG; Hourihane JOB; Lang R; Fernández-Rivas M; Christoff G; Cichocka-Jarosz E; Worm M (2018). Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register. J Allergy Clin Immunol Pract. Mar 29.
  • Worm M; Francuzik W; Renaudin JM; Bilo MB; Cardona V; Scherer Hofmeier K; Köhli A; Bauer A; Christoff G; Cichocka-Jarosz E; Hawranek T; Hourihane JO; Lange L; Mahler V; Muraro A; Papadopoulos NG; Pföhler C; Poziomkowska-Gęsicka I; Ruëff F; Spindler T; Treudler R; Fernandez-Rivas M; Dölle S (2018). Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry. Jun;73(6):1322-1330.
  • Francuzik W; Franke K; Schumann RR; Heine G; Worm M (2018). Propionibacterium acnes Abundance Correlates Inversely with Staphylococcus aureus: Data from Atopic Dermatitis Skin Microbiome. Acta Derm Venereol. Apr 27;98(5):490-495.
  • Francuzik W; Dölle S; Worm M (2018). Risk factors and treatment of refractory anaphylaxis – a review of case reports. Expert Rev Clin Immunol. Apr;14(4):307-314
  • Heine G; Hollstein T; Treptow S; Radbruch A; Worm M.(2018). 9-cis retinoic acid modulates the type I allergic immune response. J Allergy Clin Immunol. Feb;141(2):650-658.e5.
  • Kettner A; DellaCorte G; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Simonsen K; Reymond C; Spertini F (2018). Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season. J Allergy Clin Immunol. Aug;142(2):678-680.e7.
  • Worm M; Higenbottam T; Pfaar O; Mösges R; Aberer W; Gunawardena K; Wessiepe D; Lee D; Kramer MF; Skinner M; Lees B; Zielen S (2018). Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy. Sep;73(9):1812-1822.
  • Dölle S; Welter S; Ruppel E; Lehmann K; Schwarz D; Jensen-Jarolim E; Zieglmayer P; Franken P; Worm M (2018). Clinical reactivity of celery cultivars in allergic patients: Role of Api g 1. Clin Exp Allergy. 2018 Apr;48(4):424-432.
  • Bacher P; Hohnstein T; Beerbaum E; Röcker M; Blango MG; Kaufmann S; Röhmel J; Eschenhagen P; Grehn C; Seidel K; Rickerts V; Lozza L; Stervbo U; Nienen M; Babel N; Milleck J; Assenmacher M; Cornely OA; Ziegler M; Wisplinghoff H; Heine G; Worm M; Siegmund B; Maul J; Creutz P; Tabeling C; Ruwwe-Glösenkamp C; Sander LE; Knosalla C; Brunke S; Hube B; Kniemeyer O; Brakhage AA; Schwarz C; Scheffold A (2019). Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Mar 7;176(6):1340-1355.e15.
Charité Liaison Group
Continue to Third party funding projects
  • WO 541/14-1 (2013 – 2016)
  • TRR-130 TP 19 (2017 – 2021)
  • WO 541/16-2 (2019 – 2022)
  • WO 541/19-1 (2019 – 2022)
Charité Liaison Group
Continue to Introduction